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Glucose transport across glioblastoma membranes plays a crucial role in maintaining the enhanced glycolysis
typical of high-grade gliomas and glioblastoma. We tested the ability of two inhibitors of the glucose transporters
GLUT/SLC2A superfamily, indinavir (IDV) and ritonavir (RTV), and of one inhibitor of the Na/glucose antiporter type
2 (SGLT2/SLC5A2) superfamily, phlorizin (PHZ), in decreasing glucose consumption and cell proliferation of human
and murine glioblastoma cells. We found in vitro that RTV, active on at least three different GLUT/SLC2A
transporters, was more effective than IDV, a specific inhibitor of GLUT4/SLC2A4, both in decreasing glucose
consumption and lactate production and in inhibiting growth of U87MG and Hu197 human glioblastoma cell lines
and primary cultures of human glioblastoma. PHZ was inactive on the same cells. Similar results were obtained
when cells were grown in adherence or as 3D multicellular tumor spheroids. RTV treatment but not IDV treatment
induced AMP-activated protein kinase (AMPKα) phosphorylation that paralleled the decrease in glycolytic activity
and cell growth. IDV, but not RTV, induced an increase in GLUT1/SLC2A1 whose activity could compensate for the
inhibition of GLUT4/SLC2A4 by IDV. RTV and IDV pass poorly the blood brain barrier and are unlikely to reach
sufficient liquoral concentrations in vivo to inhibit glioblastoma growth as single agents. Isobologram analysis of
the association of RTV or IDV and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) or 4-methyl-5-oxo-2,3,4,6,8-
pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide (TMZ) indicated synergy only with RTV on inhibition of
glioblastoma cells. Finally, we tested in vivo the combination of RTV and BCNU on established GL261 tumors. This
drug combination increased the overall survival and allowed a five-fold reduction in the dose of BCNU.
Neoplasia (2017) 19, 364–373Address all correspondence to: Lorenzo Magrassi, Department of Clinical Surgical
Diagnostic and Pediatric Sciences, University of Pavia, Fondazione IRCCS Policlinico
S. Matteo, V.le Golgi 19, 27100 Pavia, Italy.
E-mail: lorenzo.magrassi@unipv.it
Received 21 December 2016; Revised 16 February 2017; Accepted 21 February 2017
© 2017 The Authors. Published by Elsevier Inc. on behalf of Neoplasia Press, Inc. This
is an open access article under the CC BY-NC-ND license (http://creativecommons.
org/licenses/by-nc-nd/4.0/).
1476-5586
http://dx.doi.org/10.1016/j.neo.2017.02.009Introduction
The prognosis of glioblastoma multiforme (GBM) remains poor with
a median survival of approximately 15 months [1]. The standard of
care for GBM comprises aggressive neurosurgery aiming at complete
macroscopic tumor resection, radiotherapy, and chemotherapy.
Alkylating agents like 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)
and 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-
triene-9-carboxamide (TMZ) are the only chemotherapeutic agents
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trials. Despite its longer history, BCNU has been largely supplanted
by TMZ due to easiness of administration (e.v. versus oral) and a
lower level of long-term nonhematologic toxicity compared with
nitrosureas [2]. The total cumulative dose of BCNU predicts the risk
of inducing severe pulmonary fibrosis and delayed hepatotoxicity
[3–5], thus limiting dose escalation. Despite a similar mechanism of
action, BCNU and TMZ may have a modest synergistic inhibitory
effect on glioma growth [6,7]. Moreover, resistance to TMZ
treatment does not necessarily imply resistance to BCNU both
in vitro and in vivo [8,9]. These facts generated a renewed interest in
BCNU for recurrent GBM treatment after TMZ chemotherapy, a
clinical setting where no validated treatments are available [10]. To
improve the therapeutic potential of BCNU and TMZ against GBM,
we studied if the synchronous administration of drugs blocking
glucose entry into GBM cells resulting in a reduction of the aerobic
glycolysis could potentiate the effects of the two agents. Glucose
transport into glioblastoma cells depends mainly on glucose
transporters of the GLUT/SLC2A superfamily [11–13], but other
endo and exo transporters have also been detected in glioblastoma
[14]. Both the Na/glucose antiporter type 2 (SGLT2/SLC5A2) and
HsSWEET1 (SLC50A1), the only human protein member of the
"Sugar Will Eventually be Exported Transporter" (SWEET)
superfamily, were found in glioblastoma cells [14]. Ketogenic diets
where carbohydrates are substituted by fats are potentially useful to
reduce the glycolytic metabolism of glioblastoma through a reduction
of glucose entrance in glioblastoma cells and other effects on glycolysis
[15]. However, the clinical studies available so far indicate that this
approach has only a minor effect on tumor growth and only when it is
adopted in combination with other therapies [16]. Pharmacologic
inhibition of activity of some members of GLUT/SLC2A can be
obtained in vitro and in vivo by treatment with IDV and RTV
originally developed as inhibitors of HIV-1 protease [17]. IDV is
specific for GLUT4/SLC2A4, whereas RTV is active, albeit at
different levels, against GLUT1/SLC2A1, GLUT3/SLC2A3, and
GLUT4/SLC2A4 [18,19]. In this study, we investigated the effects of
IDV, RTV, and PHZ, an inhibitor of SGLT1 and SGLT2, on
human and murine glioblastoma cells. We also studied the activity of
these drugs on glioblastoma cells in combination with BCNU or
TMZ. Because we found that RTV and BCNU have the best synergic
effect in vitro, we tested their activity in vivo against tumors obtained
by inoculating murine glioblastoma cells from the GL261 cell line
[20] in the brain of mice. Our study demonstrates that the addition
of RTV to BCNU potentiates the effect of BCNU, reaching
therapeutic efficacy at doses well below the standard recommended
for BCNU alone.
Materials and Methods
Cell Lines and Culture
We used two stable human glioblastoma cell lines, U87MG
[21,22] and Hu197 [23], and one primary human glioblastoma cell
culture, GBM-P1, obtained from a human glioblastoma sample [24]
and frozen after brief stabilization and expansion in vitro in serum-free
conditions. GBM-P1 cells were tested after less than four passages in
vitro. We also used in vitro and in vivo cells from a mouse
glioblastoma cell line, GL261 [20], and a stable GL261 clone
expressing the enhanced version of the green fluorescent protein
(eGFP) under the immediate-early human cytomegalovirus promoterselected after retroviral infection of the parental cell line. U87MG
cells were maintained in adherent cultures or as multicellular
spheroids in E-MEM medium supplemented with 10% FBS,
100 U/ml of penicillin, 0.1 mg/ml of streptomycin, and 8 μg/ml of
ciprofloxacin at 37°C and 5% CO2 atmosphere; all other stable cell
lines were cultivated in D-MEM medium supplemented with 10%
FBS, 100 U/ml of penicillin, 0.1 mg/ml of streptomycin, 2 mM
L-glutamine, and 8 μg/ml of ciprofloxacin. Primary cultures were
maintained as previously described [24]. Spheroid formation was
induced by plating the cells over standard microbiology tissue culture
petri dishes [24] and maintained as described for the adherent
cultures. Spheroids diameter varied from about 10 to 100 μm. All cell
culture reagents were purchased from Euroclone (Milan, Italy) except
for E-MEM (ATCC, Teddington, Middlesex, UK).
Microphotographs were obtained through an inverted microscope
(Leica Microsystems, Milan, Italy) equipped with phase contrast and
dark field illumination. All microphotographs were taken through a
digital camera (Canon) and the associated “Canon Utilities Remote
Capture” (Version 2.6.0.10).
Chemical Reagents and Antibodies
Drugs employed in this study were carmustine (BCNUNitrumon,
Sintesa S.A., Bruxelles, Belgium), indinavir sulfate (IDV,
Sigma-Aldrich, Milan, Italy), phlorizin (PHZ, Sigma-Aldrich),
ritonavir (RTV, Sigma-Aldrich), and temozolomide (TMZ,
Sigma-Aldrich). BCNU was resuspended in absolute ethanol; IDV
in pure water; PHZ, RTV, and TMZ in DMSO (Sigma-Aldrich) and
used at the indicated concentrations. Aphidicolin (Sigma-Aldrich)
was used to treat U87MG cells at 1-μM concentration for 24 hours to
block cell growth. Antibodies employed and dilutions were the
following: anti-actin (1:5000, cat. A4700 Sigma-Aldrich),
anti-AMPKα F6 (1:2000, cat. 2793 Cell Signaling Technology,
Danvers, MA), anti–phospho-AMPKα Thr172 40H9 (1:1000, cat.
2535 Cell Signaling Technology), anti-GLUT1/SLC2A1 (1:10,000,
cat. 07-1401 Merck-Millipore, Vimodrone, MI, Italy), anti–
Golgin-97 CDF4 (1:3000, cat. A-21270, Thermo Fisher Scientific,
Waltham, MA), anti-GFP (1:700, chicken polyclonal, Aves Labs,
Tigard, OR). Species-specific secondary antibodies labeled with
peroxidase (Thermo Fisher Scientific) or with Alexa Fluor 488
(1:500, Jackson ImmunoResearch, West Grove, PA) were employed,
respectively, for Western blot or immunohistochemistry.
Protein Extraction and Western Blot
For protein immunoblot analysis, cells were harvested and lysed in
ice-cold RIPA buffer (150 mM NaCl, 50 mM Tris-HCl pH 8.0, 1%
TritonX-100, 0.1% sodium deoxycholate, 0.1% sodium dodecyl
sulfate, 1 mM Na2VO4) supplemented with 1× “Complete Mini
Proteases Inhibitor Cocktail” (Roche, Monza, Italy). Protein samples
were quantified by Qubit fluorometer (Thermo Fisher Scientific)
following manufacturer's instructions. One hundred fifty micrograms
of protein extract was loaded per lane. Antibody binding was detected
by the “ECL Select Western Blotting Detection Kit” (GE Healthcare,
Milan, Italy).
Cell Proliferation and Glucose Consumption
Growth of U87MG, Hu197, GBM-P1, and GL261 cells was
tested after plating 5 × 105 cells per well in six-well plate. The cells
were treated with the drug of interest or the combination of drugs,
and cell counts were performed after 24 hours. For growth curve
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performed every 24 hours from the beginning of the treatment on at
least three wells. Cells were counted on a Z2 Beckman Coulter
counter (Beckman Coulter, Cassina De’ Pecchi, MI, Italy); before
counting, cells in multicellular tumor spheroids (MTS) were first
disaggregated by trypsin.
Glucose uptake in cell cultures was evaluated at the appropriate
times by sampling 300 μl of medium from the plate where the cells
were growing. After centrifugation (2000g) to remove floating cells
and cell debris, glucose was measured by a potentiometric method on
an automatic blood gas analyzer (ABL800 Flex, Radiometer, Milan,
Italy) certified for clinical use.
Construction of the Isobolograms
To distinguish synergy from additivity or antagonism of the
combination of one glucose transport inhibitor with BCNU or TMZ,
we constructed, for each combination, a specific isobologram.
Isobolograms were plotted by evaluating the concentration of two
interacting drugs giving the same effect on cell growth [25]. The
inhibiting concentration 50 (IC50) value is defined as the drug
concentration reducing by 50% the growth of treated cells compared
with control ones. We determined the IC50 of each drug separately
by plating either U87MG or GL261 cells and adding TMZ, BCNU,
RTV, IDV, or PHZ at several drug concentrations spanning their
probable range of activity. After 24 hours of treatment, the cells were
counted as described before. Each IC50 value was graphically derived
and then verified experimentally. Combination index (CI) was
defined as follows: CI = [C]A50/IC50A+[C]B50/IC50B, where [C]A50
and [C]B50 are the concentrations in combination inducing the given
effect. A CI of less than, equal to, or more than 1 indicates,
respectively, synergy, additivity, or antagonism.
Growth-inhibitory activity of the drug combinations BCNU/
RTV, TMZ/RTV, and BCNU/IDV was measured by counting the
cells after 24 hours of treatment in six-well plates and comparing the
values to the number of control cells: only the combinations giving
the same inhibitory effect of the IC50 were plotted on the
isobologram graphs. The line of additivity was constructed by
interpolating the two points corresponding to the IC50 of the two
drugs. Graphically, synergy, additivity, and antagonism are indicated
by a point plotted below, on, or above the line of additivity.
Low-Density Microvesicles Isolation
Glucose transporters are membrane-bound proteins, and their
function depends on the composition of lipids in the external or inner
membranes where they reside [26]. For this reason, GLUT/SLC2A
concentration in the cytosol is low. To increase GLUT1/SLC2A1
concentration, we purified a membrane fraction enriched in membranes
from low-density vesicles in the cells [27]. Briefly, U87MG cells were
harvested after the appropriate treatment and resuspended in the
homogenization medium (0.25 M sucrose, 1 mM EDTA, 20 mM
Hepes-NaOH, pH 7.4). The cells were homogenized in a 7-ml glass
Dounce homogenizer, and after centrifugation for 10 minutes at 1000
rpm, the pellet containing the nuclear fraction was discarded. The
supernatants were further centrifuged for 20 minutes at 14000 rpm, and
the secondary pellet containing organelles and high-density microvesicles
was discarded. Supernatants were finally centrifuged for 30 minutes at
44,000 rpm to isolate the final pellet containing the purified low-density
microvesicles (LDMs). LDMs were then lysed by RIPA buffer and
subjected to Western blot analysis as described before.Animal Experiments
Briefly, twenty-four 2- to 3-month-old female C57BlC mice were
stereotactically implanted under deep general anesthesia (isoflurane
supplemented with nitrous oxide) with 1 × 105 GL261 glioblastoma
cells. The cells were stereotactically inoculated through a burr hole by
a Hamilton syringe into the left striatum (coordinates: 1 mm
anteroposterior and 1 mm lateral from bregma, at a depth of 3 mm).
All experimental procedures were conducted in accordance with the
European Communities Council Directive of 24 November 1986
(86/609 EEC), Recommendation 18/06/2007, Dir. 2010/63/UE,
and the Italian law for care and use of experimental animals (DL116/
92) and were approved by the Italian Ministry of Health (prot.
E669C.15) and the Bioethical Committee of the University of Turin.
All animals were housed under a 12-hour light:dark cycle in an
environmentally controlled room. All experiments were designed to
minimize the numbers of animals used and their discomfort. In each
experiment, animals with tumors were allocated to one of four
groups: no treatment (controls), BCNU alone (2.5 mg/kg),
combination of RTV (100 mg/kg) and BCNU (1.5 mg/kg), or
combination of RTV (100 mg/kg) and BCNU (2.5 mg/kg). RTV was
administered every day up to the death of the animal. All drugs were
administered intraperitoneally, and treatments were started 10 days
after tumor implantation. Animals that were transplanted with
GL261 cells expressing eGFP were euthanized after the second
magnetic resonance imaging (MRI) scan. Briefly, they were
transcardially perfused under deep anesthesia (ketamine 100 mg/mg,
Ketavet, Bayern, Leverkusen, Germany; xylazine 5 mg/kg, Rompun,
Bayern, Leverkusen, Germany) with 4% paraformaldehyde in 0.12M
phosphate buffer, pH 7.2 to 7.4. The brains were dissected and cut in
50 μm–thick cryostat coronal sections. Sections were incubated
overnight at room temperature with a polyclonal anti-GFP antibody
dissolved in PBS with 1.5% donkey serum (Jackson ImmunoR-
esearch) and 0.25% Triton X-100 (Sigma Aldrich) and then exposed
for 2 hours at room temperature to secondary species-specific
antibody. The nuclei were counterstained with 4′,6-diamidino-2-
phenylindole. After processing, sections were mounted on microscope
slides with Tris-glycerol supplemented with 10% Mowiol (Calbio-
chem). Analysis of images obtained from histological sections was
performed with the open-source Java image processing program
ImageJ 1.50i [28].
MRI Experiments
MRI experiments were randomly performed on two animals in
each group to monitor tumor growth. The selected animals were
imaged 8 to 10 days post–cell inoculation and 14 days after the
beginning of the treatment. MRI were acquired at 7.1 T using a
Bruker Avance 300 spectrometer equipped with a Micro 2.5 imaging
probe and a birdcage resonator with an inner diameter of 30 mm. The
breath rate was constantly monitored throughout in vivo MRI
experiments using a respiratory probe (SAII Instruments, Stony
Brook, NY). Before MRI, mice were anesthetized by injecting a
mixture of tiletamine/zolazepam (Zoletil 100; Virbac, Milan, Italy)
20 mg/kg and xylazine (Rompun; Bayer, Milan, Italy) 5 mg/kg.
Intravenous administration of the clinically approved contrast agent
MultiHance (gadobenate dimeglumine, Bracco Diagnostics, Italy) at
0.5 mmol/kg was performed to provide T1 contrast. After the scout
image acquisition, both T2-weighted (T2w) and T1-weighted (T1w)
images were acquired to precisely locate the tumor. T2w high-
resolution anatomical images were acquired with a Turbo-Rare
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liseconds; rare factor = 8; slice thickness = 1 mm; 9 slices; field of
view = 3 cm; matrix = 384 × 384; number of averages = 5; total
imaging time = 10 minutes). T1w multislice multiecho images were
acquired 15 minutes post–Multihance injection with the same
geometry of T2w high-resolution images (repetition time =
250 milliseconds; echo time = 4.65 milliseconds; matrix = 256 ×
256; number of averages = 10; total imaging time = 10 minutes and
40 seconds). Both T2w and T1w images were acquired with coronal
geometry.
MR data analysis was carried out with Bruker Paravision 5.1
Software. The tumor area was delineated in each slice in both T2w
and T1w images by manually drawing regions of interest along tumor
borders. The 3D tumor volume was then assessed by summing up
volumes obtained through multiplication of each region of interest for
the slice thickness.
Statistical Analysis
Statistical significance was assessed by parametric (unpaired
Student’s t test) and nonparametric (Mann-Whitney test) methods.
Survival was calculated by using the date each mouse was found dead
or moribund. Survival curves were obtained by Kaplan-Meier
analysis, and significant differences in survival were evaluated by
the log-rank test by using MedCalc software, version 16.8.84.Results
RTV, IDV, and PHZ Differentially Affect Human and
Murine GBM Cell Proliferation
We determined the IC50 value of RTV, IDV, and PHZ on cell
proliferation by counting the number of cells in adherent cultures of
human U87MG or murine GL261 glioblastoma cells after 24 hours
of exposure to increasing concentrations of each drug separately. The
IC50 of RTV was 45 μM for U87MG and 55 μM for GL261. The
IC50 of IDV for U87MG was 500 μM and higher than 500 μM for
GL261. We could not determine the IC50 concentration of PHZ
because even at concentrations close to its maximum solubility in
DMSO (100 mM), it induced less than 50% of cell growth inhibition
in both cell lines (Figure 1A). At the tested concentrations of RTV,
IDV, and PHZ, the cells cultures did not show signs of increased
cytotoxicity, suggesting that, at least in the first 24 hours of treatment,
these drugs inhibited cell proliferation without inducing cell death.
After we established the IC50s of RTV and IDV in U87MG, we
tested in the same cell line if the inhibition of cell growth was stable at
longer times. The growth curves generated in the presence of the
previously determined IC50 concentrations of RTV or IDV or the
maximal PHZ concentration we used before showed that the
growth-inhibitory effects were maintained up to 72 hours (Figure 1,
B-G). By comparing the growth curves obtained with the different
drugs, we found that RTV induced more stable and prolonged
growth inhibition of U87MG cells. We also found that the same
concentration of RTV used for U87MG and GL261 cells also
inhibited growth of Hu197, an unrelated human glioblastoma cell
line, and of primary human glioblastoma cells maintained in the
absence of serum (Figure 1, A and E). MTS formed in vitro by the
aggregation of glioblastoma cells are considered a better in vitromodel
of the metabolic conditions found in glioblastoma in vivo, and they
allow better preservation of hallmark molecular alterations of cancer
than monolayer cultures [24,29]. We also tested on MTS derivedfrom U87MG cells if the same concentration of RTV was inhibitory
of cell growth, and we found that, in the presence of RTV (45 μM),
MTS were fewer and smaller compared with controls (Figure 2).
Growth curves obtained by counting glioblastoma cells after
dissociation of MTS confirmed the growth-inhibitory effect of
RTV. The results of the above experiments indicate that RTV and
IDV but not PHZ inhibit glioblastoma cell growth. However, RTV is
more powerful than IDV, and 10 times more IDV on a molar basis
are required to equal the inhibition obtained by RTV.
Inhibition of Glioblastoma Cell Growth by RTV, IDV, and
PHZ Is Proportional to the Inhibition of Glucose Uptake
We measured the uptake of glucose and the activation of aerobic
glycolysis in U87MG glioblastoma cells maintained in the presence or
absence of RTV, IDV, and PHZ by monitoring the levels of glucose
and lactate in the cell medium. We found that levels of inhibition of
glucose uptake and lactate production were proportional to the
inhibitory effect on cell growth of each drug; PHZ had no effect on
glucose consumption. Similar results were obtained when glucose
consumption and lactate production were evaluated after blocking
cell division in all culture conditions by the addition of aphidicolin,
an inhibitor of B-family of DNA polymerases [30]. Treating all
cultures both under control and experimental conditions with
aphidicolin resulted in a complete stop of cell growth; thus,
differences in cell number did not interfere with the measurements
of glucose uptake. Even in the presence of aphidicolin, RTV was the
best inhibitor of glucose consumption (Figure 3, A-C).
Glucose starvation has a profound influence on glioblastoma cell
metabolism resulting, among other effects, in a rapid increase in
intracellular AMP enhancing its binding to the γ subunit of the
AMPKα. After AMP binding, AMPKα undergoes an allosteric
transition that increases phosphorylation on Thr172 by serine/
threonine kinase 11. To confirm the biological significance of the
reduction in glucose uptake induced in U87MG cells by drug
treatments, we compared the level of AMPKα activation by
phosphorylation on Thr172 induced by the complete exhaustion of
glucose in the culture media with the effects induced by RTV or IDV
treatment (Figure 3, D and E). We found that phosphorylation of
AMPKα increased in glioblastoma cells treated by RTV at levels
comparable with those of the same cells growing in the absence of
glucose, whereas in IDV-treated cells, it did not change significantly
compared with controls (Figure 3, D and E).
RTV But Not IDV Acts Synergically with BCNU or TMZ in
Inhibiting Glioblastoma Cell Growth In Vitro
We then assessed if the addition of BCNU or TMZ to RTV and
IDV could enhance its cytostatic effect on glioblastoma cells. We
performed an isobologram analysis of the combination of RTV or
IDV with BCNU or TMZ (Figure 4, A-C). As a preliminary step for
the analysis, we determined experimentally the IC50 dose of BCNU
and TMZ that in U87MG and GL261 cell cultures resulted,
respectively, 50 μM and 40 μM for BCNU and 400 μM for TMZ.
These values are in good agreement with the values reported in the
literature [31]. The isobolograms for U87MG and GL261 cells
obtained by the simultaneous exposure of the cells to RTV and
BCNU or RTV and TMZ demonstrated, at all concentrations tested,
a clear synergism of the drug combinations. Conversely, we only
obtained indications of additivity or even antagonism when the same
cells were exposed to IDV and BCNU. Table 1 reports the
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Figure 1. In vitro effects of RTV, IDV, and PHZ on glioblastoma cells. (A) IC50 values determined for IDV, PHZ, and RTV in U87MG cells.
IC50 represents the drug concentration reducing by 50% the growth of treated cells compared with control ones. The IC50 of RTV was
45 μM, approximately 10 times lower than the IC50 of IDV (500 μM). We were unable to determine the IC50 of PHZ because PHZ never
induced 50% inhibition compared with control cells even at the maximal concentration we could dissolve PHZ in DMSO (100 mM). Y-axis
(T/NT) represents the mean value of the ratio between the number of the cells in the wells (at least 3) with the addition of the drug (T) and
the number of the cells in the control wells (NT) (at least 3). (B-G) Growth curves derived from RTV treatment of the human U87MG
glioblastoma cell line (B), GBM-P1 primary human glioblastoma-derived cells (C), human glioblastoma Hu197 cell line (D), and mouse
glioblastoma GL261 cell line (E). Growth response of U87MG glioblastoma cell line to the addition of IDV (F) or PHZ (G) was also tested
in vitro. The growth was followed up to 72 hours. RTV and IDVwere used at the IC50 concentration we previously determined for each cell
type, whereas PHZ was used at the maximal concentration we tested before. For RTV, IC50 was 45 μM for U87MG, GBM-P1, and Hu197
and 55 μM for mouse GL261 cells. RTV induced consistent growth inhibition in all glioblastoma cell cultures. Error bars depict standard
deviation.
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calculated CIs. In U87MG, the stronger synergism between BCNU
and RTV was obtained with the ratios of 1:0.7 (20 μM:13 μM) and
1:2.5 (10 μM:22 μM) and the similar CI of 0.7. Comparable CIsvalues (0.7) were also obtained for the TMZ-RTV combination. We
obtained similar results when we tested the different drug
combinations on GL261 cells with a CI of 0.7 for the
BCNU-RTV combination that is the same obtained in U87MG cells.
Figure 2. Microphotographs of U87MG cells growing in adherence (A-D) or in MTS (E-H), control conditions (A, C, E, and G), or after
addition of RTV (45 μM) (B, D, F, and H). After RTV treatment, cell proliferation is reduced as shown by the reduction both in the number of
adherent cells (B, D) and in the size and abundance of MTS (F, H). Scale bars are in μm.
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Figure 3. Twenty-four–hour treatment of RTV inhibits glucose consumption and lactate production in U87MG cells. After RTV treatment,
we measured the concentration of glucose (A) and lactate (B) in the medium, and we observed a significant decrease in glucose uptake
and lactate production; this reduction indicates a significant inhibition of glycolysis. As RTV treatment reduces cell proliferation, we
performed the experiment in the presence of aphidicolin at a concentration blocking cell division (1 μM) to maintain a comparable number
of cells in untreated (NT) and RTV-treated (RTV) cultures (C). Histograms derived from two independent experiments; at least three wells
per experiment. Asterisk indicates values from controls (P b .05 unpaired t test). Error bars indicate standard deviation. (D) Western blot
analysis: AMPKα activation was demonstrated in U87MG cells by an increase in the level of threonine (T172) phosphorylation compared
with control; AMPKαwas activated by metabolic stress (Stress) or RTV (45 μM) treatment; IDV (500 μM) treatment did not induce AMPKα
activation. Act: immunoreactivity for actin. On the right, the corresponding molecular weights are indicated (kDa). (E) Histogram
representing the results of the densitometric analysis of Western blot bands of three independent experiments confirming that AMPKα
activation is significantly induced by Stress or RTV but not by IDV. “a.u.” (arbitrary units) indicates differences in AMPK activation in
stressed (Stress), RTV- or IDV-treated versus untreated cells. Asterisks indicate P b .05 compared with NT sample. Error bars indicate
standard deviation.
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Figure 4. (A) Isobolograms analysis of inhibition of growth of U87MG cells (A-C) and effects of RTV and IDV treatment on GLUT1/SLC2A1
transporter levels in U87MG cells (D-E). (A-C) The “line of additivity” connects the values of the IC50 of the two drugs used in combination,
thus separating the quadrant into two parts; points plotted below the line of additivity indicate synergy (activity of the combination is
larger than expected for the simple combination of the two drugs), whereas points above the line indicate antagonism (activity of the
combination is lower than the expected for the simple combination of the two drugs). BCNU-RTV: (A) The two drugs at all tested
concentrations show synergic activity. TMZ-RTV: (B) The two drugs at all tested concentrations show synergic activity. BCNU-IDV: (C) The
two drugs show addictive or antagonistic behavior at all concentrations except for the highest, whenwe obtained an indication of minimal
synergic activity. (D) Western blot of total lysates of U87MG cells: RTV reduced the level of GLUT1/SLC2A1 immunoreactivity, whereas
IDV increased GLUT1/SLC2A1 level compared with untreated cells (NT). The same membrane was stripped and reacted with an antibody
against actin (Act) whose level was similar in all samples. (E) As in D, but the cells were fractionated, and only the fraction containing the
LDMs, where the GLUTs-containing vesicles reside, was analyzed by Western blot. As in the total extract, the GLUT1/SLC2A1 signal was
decreased only by RTV treatment. The same membrane was stripped and reacted with an antibody against Golgin-97 whose level was
similar in all samples. Numbers indicate the molecular weights in kDa.
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GLUT1/SLC2A1
IDV is a more powerful and specific inhibitor of GLUT4/SLC2A4
and has little or no inhibitory activity on GLUT1/SLC2A1 and
GLUT3/SLC2A3, whereas RTV is less efficient than IDV in
inhibiting GLUT4/SLC2A4 (Figure 4D). However, because of its
broader specificity, RTV inhibits the activity of multiple members of
the GLUT/SLC2A superfamily [18,19]. Because multiple members
of the GLUT/SLC2A superfamily are expressed in glioblastoma cells,
we hypothesized that strong inhibition of GLUT4/SLC2A4 activity
by IDV could result in upregulation of other members of the
superfamily to compensate for the reduced uptake of glucose. We
purified the LDM fraction from U87MG cells after 24 hours of RTV
(45 μM) or IDV (500 μM) treatment and from untreated cells. The
LDM fraction is enriched in vesicles and cell membranes containing
members of the GLUT/SLC2A superfamily. We analyzed the LDM
fractions from the different treatment conditions by Western blot
using a monoclonal antibody against GLUT1/SLC2A1, and we
found that RTV treatment decreased the level of GLUT1/SLC2A1,
whereas IDV did not reduce but slightly increased the level of
GLUT1/SLC2A1 compared with untreated cells (Figure 4E).RTV Acts Synergically with BCNU in Inhibiting Glioblastoma
Cell Growth In Vivo
We generated glioblastoma in mice brain by stereotactically
injecting 1 × 105 GL261 cells into the left striatum of adult mice.
Tumor formation was evaluated in randomly chosen mice by contrast
MRI 10 days after inoculation of the cells. Mice where then divided
into four groups I) control, II) mice receiving BCNU (2.5 mg/kg,
i.p.), III) mice receiving both BCNU (1 mg/kg, i.p.) the first day and
RTV (100 mg/kg, i.p.) every day up to death or sacrifice of the
animal, and IV) mice receiving both BCNU (2.5 mg/kg, i.p.) the first
day and RTV (100 mg/kg, i.p.) every day up to death or sacrifice of
the animal. Animals receiving BCNU alone or in combination that
were still surviving 27 days after tumor inoculation received a second
i.p. injection of BCNU at the same concentration used for the first.
Animals initially submitted to MRI were rescanned 2 weeks after the
first examination (Figure 5). Mice receiving an inoculum of GL261
cells expressing eGFP were euthanized after the second MRI and
processed for histology to confirm the neoplastic nature of the
alterations seen in the MRI (Figure 6A). The MRI scans
demonstrated that the average tumor volume in mm3 of control
mice was 39.33 (S.D. ±38.88), of mice treated by 2.5 mg/kg BCNU
Table 1. Combination Index Analysis
BCNU (μM) RTV (μM) BCNU RTV CI
IC50EQ IC50EQ Ratio CI = (d1/50) + (d2/45)
50 0 1.0000 0.0000
40 1 0.8000 0.0227 1:0.03 0.82 Synergy
20 13 0.4000 0.2955 1:0.7 0.70 Synergy
10 22 0.2000 0.5000 1:2.5 0.70 Synergy
5 30 0.1000 0.6818 1:6.8 0.88 Synergy
0 45 0.0000 1.0000
TMZ
(μM)
RTV
(μM) TMZ RTV CI
IC50EQ IC50EQ Ratio CI = (d1/400) + (d2/45)
400 0 1.0000 0.0000
300 1 0.7500 0.0227 1:0.003 0.77 Synergy
200 10 0.5000 0.2273 1:0.05 0.73 Synergy
100 20 0.2500 0.4545 1:0.2 0.70 Synergy
50 25 0.1250 0.5682 1:0.5 0.69 Synergy
10 30 0.0250 0.6818 1:3 0.71 Synergy
0 45 0.0000 1.0000
BCNU
(μM)
IDV
(μM) BCNU IDV CI
IC50EQ IC50EQ Ratio
CI = (d1/50)
+ (d2/500)
50 0 1.0000 0.0000
40 50 0.8000 0.1100 1:1.25 0.91 Synergy
40 100 0.8000 0.2200 1:2.50 1.02 Additivity
30 200 0.6000 0.4400 1:6.67 1.04 Additivity
30 300 0.6000 0.6600 1:10 1.26 Antagonism
20 300 0.4000 0.6600 1:15 1.06 Additivity
0 500 0.0000 1.0000
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100 mg/kg RTV was 27 (S.D. ± 20.53), and of mice treated by
2.5 mg/kg BCNU and 100 mg/kg RTV was 20 (S.D. ±15.67).
Although a trend associating a reduction of tumor volume with the
addition of RTV to BCNU is apparent, it did not reach statisticalFigure 5. The effect of BCNU alone and BCNU+RTV on tumor growth
days just before the start of treatment, and 14 days later. The imag
(CTRL), BCNU (BCNU 1.5 mg/kg alone), BCNU (same as before). and
the results of MRIs performed on day 10 after tumor inoculation, wh
days after the start of treatment (24 days after the inoculum). For e
whereas in the second column, T1-weighted images after gadolinium
images delimit the area of the tumor, whereas the tumor is indicatedsignificance. However, the Kaplan-Meier survival analysis showed a
significant statistical difference in overall survival for mice treated by
RTV and BCNU compared with control mice or mice treated by
BCNU alone (χ2 11.74, degrees of freedom 3, P = .0083)
(Figure 6B). Interestingly, both tumor volume and overall survival
of mice receiving BCNU and RTV were not significantly different in
mice treated with 1 mg/kg compared with 2.5 mg/kg of BCNU.
Discussion
Highly efficient glucose uptake through glucose transporters is
important for brain tumor initiating cell growth and survival in
glioblastoma [32]. Increased glucose uptake is instrumental in
maintaining an enhanced glycolic activity that is essential for survival
of the mesenchymal subtype of glioblastoma [33]. Furthermore,
long-term treatment of glioblastoma cells with TMZ, the most
common chemotherapeutic agent used in the adjuvant treatment of
GBM, upregulates expression of GLUT/SLC2A family members
[34]. Inhibition of glucose uptake and/or aerobic glycolysis are thus
considered potentially important targets for glioblastoma therapy
[35]. We exploited the off-target inhibitory effects of RTV on
GLUT1/SLC2A1, GLUT4/SLC2A4, and other members of the
GLUT/SLC2A superfamily to inhibit the growth of human and
murine glioblastoma cells both in vitro and in vivo. Our results
demonstrated that the growth-inhibitory effect of RTV treatment on
human and murine glioblastoma cells parallels its effects on glucose
uptake as predicted from its inhibition of multiple glucose
transporters of the GLUT/SLC2A superfamily [18,19]. On the
contrary, IDV, another HIV protease inhibitor, whose off-target
effects are limited to GLUT4/SLC2A4 [17], resulted to be less active
in inhibiting glioblastoma cell growth. However, both RTV and IDV
reach cerebrospinal fluid concentrations in vivo that are less than one
order of magnitude of their plasma concentration [36]. Interestingly,
others, after having considered the potential proteasomal inhibitory
activity of RTV, unsuccessfully attempted to inhibit in vivo the
growth of a 9L rat gliosarcoma tumor model by administering RTV as
a single agent [37]. On the contrary, RTV is active in vitro as a singlein vivo. Mice were inoculated with GL261 cells and imaged after 10
es are divided into three groups according to treatments: control
RTV (100 mg/kg). In each group, the first row (pretreatment) shows
ereas the second row (post treatment) shows images obtained 14
ach animal, in the first column, T2-weighted images are reported,
injection are displayed. The stippled lines present in T2-weighted
by an arrow in the corresponding T1-weighted images.
Figure 6. (A) eGFP-expressing GL261 glioma cells grow and infiltrate the host brain 2 weeks after the initial inoculum; control animal.
Microphotograph showing a coronal section of the tumor-bearing brain. Cell nuclei are stained by 4′,6-diamidino-2-phenylindole. GL261
cells fluoresce in green. EGFP-positive GL261 glioma cells spread into the left striatum and adjacent structures, occupying 4.9% of the
brain hemispheres. The area boxed is shown at higher magnification in the inset. Scale bars: 30 μM in A and 10 μM in the inset. (B)
Kaplan-Meier analysis of survival of mice bearing GL261 gliomas treated by BCNU alone or BCNU and different amounts of RTV as
indicated in the box. Each treatment group of mice is indicated by a different line texture and color. Control mice, inoculated with GL261
cells and left untreated, are indicated in green. Mice inoculated with GL261 cells and injected i.p. 12 days after with BCNU (2.5 mg/kg) are
indicated in orange. Mice inoculated with GL261 cells and injected i.p. 12 days after with BCNU (2.5 mg/kg) and RTV (100 mg/kg) are
indicated in red. After the initial administration, BCNU was administered every 2 weeks, whereas RTV i.p. injections were repeated daily
up to the death of the mice. Comparison of survival curves (log-rank test) showed a significant effect of the addition of RTV on survival
compared with controls and BCNU alone (χ2: 12.7816; degrees of freedom 3; P = .0051).
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high-grade glioma cells [37,38]. The results of our isobologram
analysis of the combined effects of RTV and BCNU or TMZ on
human and murine glioblastoma cells revealed that RTV in vitro does
synergize the growth-inhibitory effects of both chemotherapeutic
agents, whereas IDV when used in combination with BCNU is, at its
best, only additive. These results suggest that multiple glucose
transporter inhibition is necessary for the synergic effect of RTV with
BCNU or TMZ. We preferred to test in vivo the combination of
RTV with BCNU because TMZ treatment upregulates expression of
GLUT/SLC2A family members [34], therefore possibly interfering
with RTV action at the low doses achievable in the cerebrospinal
fluid. Furthermore, hematologic, hepatic, and pulmonary cumulative
dose-limiting toxicity is worse with BCNU compared with TMZ [2].
The possibility of obtaining a similar antiglioblastoma response with
single-dose reduction by combining BCNU with RTV is thus more
relevant clinically for BCNU, which could in principle be
administered for longer times before reaching its cumulative limiting
dose. The results of the in vivo experiments show that RTV (100 mg/kg)
synergizes the growth-inhibitory action of BCNU, prolonging mice
survival even at doses of BCNU as low as 1 mg/kg that are at least five
times lower than the lower dose commonly administered tomice for brain
tumor therapy [39] and just two times the dose administered, without
apparent toxicity, to reduce the amyloid plaque burden in an Alzheimer's
mouse model [40]. The dose of RTV we employed in vivo is the dose
employed as single agent against the rat 9L gliosarcoma model that failed
to give any indication of prolonged survival [37]. However, the results of
our isobologram analysis on glioblastoma cells suggest that, when used in
combination with BCNU, the dose of RTV could be reduced to
minimize the negative effects of chronic RTV administration like insulin
resistance, dyslipidemia, and lipodystrophy [41]. Interestingly, thecurrent clinical indication for RTV is as a pharmacokinetic enhancer of
other HIV protease inhibitors, predominantly due to its inhibitory effect
on P-glycoprotein and the cytochrome P450 3A4 isoenzyme [42]. This
effect could also enhance in vivo the activity of BCNU against high-grade
gliomas, allowing further modulation of the dose. In conclusion, our
findings support the idea that RTV, despite its poor penetration of the
blood-brain barrier, synergizes with BCNU in vitro and in vivo, allowing
a significant decrease in the level of BCNU necessary to control the
growth of GBM.Considering that both and BCNU are already approved
and their side effects well known, a clinical study on high-grade glioma
patients based on drug repositioning of RTV in combination with
BCNU or TMZ seems interesting.
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